한글목차

아테졸리주맙 시장은 2025년에는 36억 4,000만 달러로 추정되고, 2032년에는 106억 7,000만 달러에 이를 것으로 예상되며, 2025-2032년 CAGR 16.6%로 성장이 예측되고 있습니다.

아테졸리주맙은 획기적인 면역 요법 약물로 여러 유형의 암 치료에 혁명을 일으켰습니다. 로슈가 개발한 이 치료용 항체는 암세포가 면역체계의 검출을 회피할 수 있게 하는 프로그램 사 리간드1(PD-L1) 단백질을 저해합니다. PD-L1을 저해함으로써 아테졸리주맙은 암세포를 인식하고 공격하는 면역계의 힘을 이끌어내 환자의 예후 개선으로 이어집니다.

시장 역학 :

아테졸리주맙 시장은 몇 가지 중요한 요인들로 인해 큰 성장을 이루고 있습니다. 첫째, 세계의 암 이환율 상승으로 효과적인 치료 옵션에 대한 수요가 높아지고 있습니다. 아테졸리주맙은 폐암, 방광암, 유방암 등 다양한 암에서 유망한 결과를 보이기 때문에 대응 가능한 환자 집단이 확대되고 있습니다. 게다가, 면역요법의 이점에 대한 의식 증가 및 표적요법에 대한 선호도는 시장의 성장을 더욱 뒷받침하고 있습니다.

그러나 많은 기회가 있음에도 불구하고 시장을 억제하는 요인도 있습니다. 아테졸리주맙의 고가는 큰 장벽이며, 저소득 국가와 일부 신흥국 시장에서도 환자에 대한 접근을 제한하고 있습니다. 게다가, 신약의 승인 과정이 복잡하고 시간이 걸리는 것이 시장 진입의 과제가 되고 있습니다. 또한, 대체 면역요법 치료의 출현과 바이오시밀러의 가용성도 시장 성장을 방해할 수 있습니다.

하지만 아테졸리주맙 시장은 향후 시장 개척에 헤아릴 수 없는 가능성을 가지고 있습니다. Novartis, Pfizer, Merck, AstraZeneca, Bristol-Myers Squibb, BeiGene, Innovent Biologics, Genentech, AbbVie 등 주요 기업들이 연구 개발을 진행하고 있기 때문에 혁신적인 치료 옵션이 탄생하여 시장이 더욱 확대될 것으로 기대됩니다. 정밀의료에 대한 관심 증가 및 동반자 진단 약물의 개발은 또한 아테졸리주맙을 이용한 개인화된 치료 접근법의 기회를 창출하고 있습니다.

본 조사의 주요 특징

• 본 보고서에서는 세계의 아테졸리주맙 시장에 대해 2024년을 기준연도로 한 예측 기간(2025-2032년) 시장 규모 및 연간 평균 성장률(CAGR%) 등 상세한 분석을 제공합니다.
• 다양한 부문에 걸친 잠재적인 수익 기회를 밝히고, 이 시장의 매력적인 투자 제안의 매트릭스에 대해 해설했습니다.
• 또한 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채용하는 경쟁 전략 등에 관한 중요한 인사이트도 제공합니다.
• 본 조사에서 소개하는 세계의 아테졸리주맙 시장에서 주요 기업 프로파일에는 Roche, Novartis, Pfizer, Merck, AstraZeneca, Bristol-Myers Squibb, BeiGene, Innovent Biologics, Genentech, AbbVie 등이 포함됩니다.
• 본 보고서의 인사이트를 통해 마케팅 담당자나 경영진은 장래의 제품 발매, 업그레이드, 시장 확대, 마케팅 전술에 관한 정보에 근거한 의사 결정을 실시할 수 있습니다.
• 세계의 아테졸리주맙 시장 보고서는 투자자, 공급업체, 제품 제조업체, 판매자, 신규 참가자, 재무 분석가 등 업계의 다양한 이해 관계자를 지원합니다.
• 이해관계자는 세계의 아테졸리주맙 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정이 용이해집니다.

목차

제1장 조사의 목적 및 전제조건

• 조사 목적
• 전제조건
• 약어

제2장 시장 전망

• 보고서 설명
  • 시장 정의 및 범위
• 주요 요약
• 일관된 기회 지도(COM)

제3장 시장 역학, 규제 및 동향 분석

• 시장 역학
  • 성장 촉진요인
• 세계적으로 암 발생률 상승
• 효과적인 치료법에 대한 수요 증가
  • 성장 억제요인
• 아테졸리주맙의 고비용
  • 기회
• 주요 기업에 의한 지속적인 연구개발의 대처
• 영향 분석
• 주요 하이라이트
• 규제 시나리오
• 제품 출시 및 승인
• PEST 분석
• Porter's Five Forces 분석
• 합병 및 인수 시나리오

제4장 세계의 아테졸리주맙 시장 : 코로나바이러스(COVID-19) 팬데믹의 영향

• COVID-19 역학
• 공급측 및 수요측 분석
• 경제에 미치는 영향

제5장 세계의 아테졸리주맙 시장 : 약제 클래스별(2020-2032년)

• PD-L1 억제제
• PD-1 억제제
• CTLA-4 억제제
• 면역조절제
• 기타

제6장 세계의 아테졸리주맙 시장 : 적응증별(2020-2032년)

• 폐암
• 방광암
• 흑색종
• 호지킨 림프종
• 두경부암
• 기타

제7장 세계의 아테졸리주맙 시장 : 유통 채널별(2020-2032년)

• 병원 약국
• 소매 약국
• 온라인 약국

제8장 세계의 아테졸리주맙 시장 : 최종 사용자별(2020-2032년)

• 병원
• 재택치료
• 전문 클리닉
• 기타

제9장 세계의 아테졸리주맙 시장 : 지역별(2020-2032년)

• 북미
• 유럽
• 아시아태평양
• 라틴아메리카
• 중동 및 아프리카

제10장 경쟁 구도

• Roche
• Novartis
• Pfizer
• Merck
• AstraZeneca
• Bristol-Myers Squibb
• BeiGene
• Innovent Biologics
• Genentech
• AbbVie

제11장 섹션

• 조사 방법
• 출판사에 대해

영문목차

Atezolizumab Market is estimated to be valued at USD 3.64 Bn in 2025 and is expected to reach USD 10.67 Bn by 2032, growing at a compound annual growth rate (CAGR) of 16.6% from 2025 to 2032.

Atezolizumab is a breakthrough immunotherapy drug that has revolutionized the treatment of multiple types of cancer. This therapeutic antibody, developed by Roche, inhibits the programmed death-ligand 1 (PD-L1) protein, which enables cancer cells to evade immune system detection. By blocking PD-L1, atezolizumab unleashes the power of the immune system to recognize and attack cancer cells, leading to improved patient outcomes.

Market Dynamics:

The market for atezolizumab is experiencing significant growth, driven by several key factors. Firstly, the rising incidence of cancer globally is increasing the demand for effective treatment options. Atezolizumab has shown promising results in various cancers, including lung, bladder, and breast cancer, thus expanding the addressable patient population. Additionally, the growing awareness about the benefits of immunotherapy and the preference for targeted therapies are further bolstering market growth.

However, despite the numerous opportunities, there are certain factors restraining the market. The high cost of atezolizumab is a major barrier, limiting access to patients in lower-income countries and even in some developed markets. Additionally, the complex and lengthy regulatory approval process for new drugs poses a challenge for market entry. Moreover, the emergence of alternative immunotherapy treatments and the availability of biosimilars could also hinder market growth.

Nevertheless, the market for atezolizumab holds immense potential for future development. The ongoing research and development efforts by key players such as Novartis, Pfizer, Merck, AstraZeneca, Bristol-Myers Squibb, BeiGene, Innovent Biologics, Genentech, and AbbVie are expected to yield innovative treatment options, expanding the market further. The increasing focus on precision medicine and the development of companion diagnostics are also creating opportunities for personalized treatment approaches using atezolizumab.

Key Features of the Study:

• This report provides in-depth analysis of the global Atezolizumab market, including market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), with 2024 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
• Key players in the global Atezolizumab market profiled in this study include Roche, Novartis, Pfizer, Merck, AstraZeneca, Bristol-Myers Squibb, BeiGene, Innovent Biologics, Genentech, and AbbVie.
• Insights from this report would enable marketers and management authorities to make informed decisions regarding future product launches, upgrades, market expansion, and marketing tactics.
• The global Atezolizumab market report caters to various stakeholders in the industry, including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders will have ease in decision-making through various strategy matrices used for analyzing the global Atezolizumab market.

Atezolizumab Market Segmentation:

• By Drug Class:
  • PD-L1 Inhibitors
  • PD-1 Inhibitors
  • CTLA-4 Inhibitors
  • Immunomodulators
  • Others
• By Indication:
  • Lung Cancer
  • Bladder Cancer
  • Melanoma
  • Hodgkin's Lymphoma
  • Head and Neck Cancer
  • Others
• By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Route of Administration:
  • Intravenous
  • Oral
  • Others
• By End User:
  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
• Company Profiles
  • Roche
  • Novartis
  • Pfizer
  • Merck
  • AstraZeneca
  • Bristol-Myers Squibb
  • BeiGene
  • Innovent Biologics
  • Genentech
  • AbbVie

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Atezolizumab, By Drug Class
  • Market Atezolizumab, By Indication
  • Market Atezolizumab, By Distribution Channel
  • Market Atezolizumab, By End User
  • Market Atezolizumab, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
• Rising incidence of cancer globally
• Increasing demand for effective treatment options
  • Restraints
• High cost of atezolizumab
  • Opportunities
• Ongoing research and development efforts by key players
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product launch/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Global Atezolizumab Market - Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Supply Side and Demand Side Analysis
• Economic Impact

5. Global Atezolizumab Market, By Drug Class, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• PD-L1 Inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• PD-1 Inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• CTLA-4 Inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Immunomodulators
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)

6. Global Atezolizumab Market, By Indication, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2023and 2032 (%)
  • Y-o-Y Growth Analysis, 2021- 2032
  • Segment Trends
• Lung Cancer
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Bladder Cancer
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Melanoma
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Hodgkin's Lymphoma
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Head and Neck Cancer
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)

7. Global Atezolizumab Market, By Distribution Channel, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2023and 2032 (%)
  • Y-o-Y Growth Analysis, 2021- 2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)

8. Global Atezolizumab Market, By End User, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2023and 2032 (%)
  • Y-o-Y Growth Analysis, 2021- 2032
  • Segment Trends
• Hospitals
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Homecare
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Specialty Clinics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)

9. Global Atezolizumab Market, By Region, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, By Country, 2023and 2032 (%)
  • Y-o-Y Growth Analysis, For Country 2021-2028
  • Country Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
• Middle East & Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)

10. Competitive Landscape

• Roche
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Novartis
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Pfizer
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Merck
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• AstraZeneca
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Bristol-Myers Squibb
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• BeiGene
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Innovent Biologics
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Genentech
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• AbbVie
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Analyst Views

11. Section

• Research Methodology
• About us